Liquidia (NASDAQ:LQDA) Insider Sells $562,283.13 in Stock

Liquidia Corporation (NASDAQ:LQDA) insider Jason Adair sold 7,863 shares of the company’s stock in a transaction that occurred on Monday, July 13th. The stock was sold at an average price of $71.51, for a total value of $562,283.13. Following the completion of the sale, the insider directly owned 217,126 shares of the company’s stock, valued at approximately $15,526,680.26. This represents a 3.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jason Adair also recently made the following trade(s):

• On Monday, April 27th, Jason Adair sold 688 shares of Liquidia stock. The shares were sold at an average price of $41.65, for a total transaction of $28,655.20.

Liquidia Trading Down 3.2%

LQDA stock opened at $75.27 on Friday. The company has a market capitalization of $6.69 billion, a PE ratio of 537.68 and a beta of 0.55. Liquidia Corporation has a one year low of $14.04 and a one year high of $82.96. The company’s 50 day moving average price is $67.74 and its two-hundred day moving average price is $48.10. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The firm had revenue of $132.87 million during the quarter, compared to analyst estimates of $119.44 million. The firm’s revenue was up 4187.1% on a year-over-year basis. As a group, analysts predict that Liquidia Corporation will post 3.02 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in LQDA. Farallon Capital Management LLC lifted its position in shares of Liquidia by 102.1% in the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock worth $194,783,000 after purchasing an additional 4,326,876 shares during the period. TCG Crossover Management LLC bought a new position in Liquidia in the third quarter worth about $38,887,000. MPM Bioimpact LLC raised its stake in Liquidia by 600.4% in the fourth quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock worth $48,316,000 after buying an additional 1,200,869 shares in the last quarter. Voloridge Investment Management LLC bought a new position in Liquidia in the third quarter worth about $12,571,000. Finally, Bank of America Corp DE lifted its holdings in Liquidia by 18.7% in the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after buying an additional 360,372 shares during the period. 64.54% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have weighed in on LQDA shares. Bank of America reissued a “neutral” rating and issued a $79.00 price target (up from $64.00) on shares of Liquidia in a research note on Monday, June 29th. Jefferies Financial Group reaffirmed a “buy” rating and set a $60.00 price objective on shares of Liquidia in a research note on Monday, May 11th. HC Wainwright upped their price target on Liquidia from $67.00 to $75.00 and gave the company a “buy” rating in a research report on Friday, June 5th. Wall Street Zen cut Liquidia from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 27th. Finally, Oppenheimer set a $75.00 price objective on Liquidia in a research report on Friday, June 5th. Three research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $68.88.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).